Literature DB >> 29737660

On the history of Cinchona bark in the treatment of Malaria.

Henrik Permin, Svend Norn, Edith Kruse, Poul R Kruse.   

Abstract

How and when the medical value of Cinchona bark was discovered is obscure, but it is said that the powder was given to a European for malaria for the first time in the 1630s. The bark was brought to Europe by Spanish missionaries and it was recommended by the cardinal Juan de Lugo. In the 1660s, the use of Cinchona bark became known in England - and in Denmark by Thomas Bartholin. It was used for the treatment of malaria, but several debates on its value continued up to the 1730s. However, successful treatment of malaria was obtained by Thomas Sydenham, Robert Tabor and Francesco Torti. Sydenham emphasized a modern view that Cinchona bark was a unique specific drug for the treatment of malaria, and the treatment was fully accepted when Torti's Therapeutice specialis appeared. In the early 18th century, botanical expeditions were arranged in search of the most valuable Cinchona species for cultivation. The content of quinine was impor- tant, and determination of quinine was realized when Pierre Pelletier and Joseph Caventou isolated the alkaloid from the bark in 1820. Dutch plantations and quinine industry dominated the market, but the supply of quinine came to an end when the Japanese occupied Indonesia in 1942, cutting off the rest of the world from the main supplies of Cinchona. Synthetic antimalarials were developed and chloroquine became the drug of choice, but the intensive use of these drugs caused drug resistance. Chloroquine-resistant strains of P. falciparum are now treated with other drugs as artemisinin and artemether.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 29737660

Source DB:  PubMed          Journal:  Dan Medicinhist Arbog        ISSN: 0084-9588


  2 in total

1.  Anti-malarial activity of traditional Kampo medicine Coptis rhizome extract and its major active compounds.

Authors:  Awet Alem Teklemichael; Shusaku Mizukami; Kazufumi Toume; Farhana Mosaddeque; Mohamed Gomaa Kamel; Osamu Kaneko; Katsuko Komatsu; Juntra Karbwang; Nguyen Tien Huy; Kenji Hirayama
Journal:  Malar J       Date:  2020-06-08       Impact factor: 2.979

2.  Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.

Authors:  Sultan Ayoub Meo; Syed Ziauddin A Zaidi; Trisha Shang; Jennifer Y Zhang; Thamir Al-Khlaiwi; Ishfaq A Bukhari; Javed Akram; David C Klonoff
Journal:  J King Saud Univ Sci       Date:  2020-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.